Associate Professor of the Department of Oncology
Director of the Adolescent and Young Adult Oncology Program, McGill University
Director of the Oncology Clinical Research Program at the Lady Davis Institute, Jewish General Hospital
G.I. Oncology Tumor Site chairperson for McGill University and the Rossy Cancer Network
Dr. Kavan is currently a medical oncologist practicing at the Jewish General Hospital and McGill University Health Center and has been since 2000. He completed his medical school training at Charles University in Prague, Czech Republic and completed his internship/residency in Pediatrics and Medicine at Charles University Medical School. After that he completed his fellowship in Oncology at the same university in Prague. He was later a visiting fellow and scientist at the Texas Children’s Cancer Center, Baylor College of Medicine, in Houston, USA and a visiting scientist for a short time in: Memphis, USA; Hannover, Germany; Leeds, UK; Paris, France; and Vancouver, British Columbia. He completed his PhD in Oncology Bone Marrow Transplants in 2001.
His honors and awards include: Czech Ministry of Health Award for Grant 0765-5: Late Effects in Pediatric Oncology; the Josef Hlavka Literary Award for the Book of the Year: Bone Marrow Transplantation, and an Adolescent and Young Adult Cancer Award 2010 for lectures and publications. He has also presented at 93 invited lectures within the European Union, the U.S.A. and other international meetings; and more than 130 lectures in Canada since 2007. Dr. Kavan also has 51 peer reviewed publications and 117 poster presentations since 2007, and 5 monographies and 5 CME educational programs since 2008. Dr. Kavan is a member of many national and international cancer organizations, including ASCO and ESMO. He also serves as a reviewer of publications, presentations and grants. Dr. Kavan is the principle or co-investigator of 11 large research grants received since 2003.
Major Research Activities
His current clinical specialties are Gastrointestinal Oncology with neuroendocrine tumors and GIST included as well as Neurooncology. He has research interests such as phase one, two, three, and four clinical studies and new drug development; therefore Dr. Kavan is a CCTG NCIC representative helping to conduct clinical trials at McGill University, within Quebec, and the rest of Canada.
A. Mamo, PhD,* A. Baig, MD,* M. Azam,* Y.S. Rho, MD,* S. Sahebjam, MD,* T. Muanza, MD,† S. Owen, MD,‡ K. Petrecca, MD,§ M.C. Guiot, MD,‖ J. Al-Shami,# R. Sharma, MD,# and P. Kavan, MD PhD*. Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol. 2016 Oct; 23(5): e468–e471.
Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, Batist G, Azoulay L, Kavan P. Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study.; Clin Colorectal Cancer. 2017 Mar 21.
Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore). 2017 Apr;96(16): e6544.
Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, Dalfen R, Dalzell MA. Time course of upper limb function and return-to-work post-radiotherapy in young adults with breast cancer: a pilot randomized control trial on effects of targeted exercise program. ; J Cancer Surviv. 2017 May 3.